Overview
Updated 14 Jul 2026
Gary Schiller, MD, is Professor of Medicine (Professor-in-Residence) at University of California Los Angeles David Geffen School of Medicine, Department of Medicine, Division of Hematology-Oncology. The public record shows 735 publications with 23,227 citations (h-index 72), centered on Acute Myeloid Leukemia Research, Multiple Myeloma Research and Treatments, Chronic Myeloid Leukemia Treatments. It also documents an investigator role on 23 registered clinical trials, industry payments reported by 36 companies.
- Most recent indexed publication: 2026 · Journal of clinical oncology
- Top research focus: Acute Myeloid Leukemia Research
- 23 registered trials on ClinicalTrials.gov
- Open Payments reporting from 36 companies
Generated from the cited public record · current as of 14 Jul 2026. Every fact links its source below.
Indications focusfrom trials led + research topics
Research focusOpenAlex concept fingerprint
Drugs & moleculesacross trials, industry payments and publications
Works withtrial sponsors and companies reporting payments
Scholarshipindexed output and impact (OpenAlex)
View publications ↓Distinct works indexed by OpenAlex, matched via ORCID; 12 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 264.
Clinical & industrytrials, payments and federal funding
Federally funded research awards.
Clinical trials
Updated 14 Jul 2026
Listed as an investigator on 23 registered studies on ClinicalTrials.gov. The most recent:
- A Phase 2, Open-Label Study of DISC-3405 in Participants With Polycythemia Vera (PV)
Sponsor: Disc Medicine, Inc
InvestigatorPhase 2RecruitingNCT06985147 - Study of EN-374 Gene Therapy in Participants With X-Linked Chronic Granulomatous Disease
Sponsor: Ensoma
InvestigatorPhase 1/PHASE2RecruitingNCT06876363 - Evaluate the Safety, Tolerability, Pharmacokinetic Profile, Efficacy of Bl-M11D1
Sponsor: SystImmune Inc.
InvestigatorPhase 1RecruitingNCT06714591
Industry payments
Updated 14 Jul 2026
36 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Karyopharm Therapeutics Inc.Program year20255 payments
- Geron CorporationProgram year20253 payments
- Autolus IncProgram year20253 payments
NIH funding
We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →
Congress activity
Updated 14 Jul 2026
193 congress contributions (2004–2025) across AACR, ASCO, ASH, ESMO per OpenAlex. The most recent:
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 14 Jul 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model.
Journal of clinical oncology
2026
Most-cited worksby citation count (OpenAlex)
Contact
An office address from a public listing. This research profile has no federal registry record to draw from.
Office address
Geffen Hall, 885 Tiverton Drive, Los Angeles, CA 90095
Network
Updated 14 Jul 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Background & recognition
Updated 14 Jul 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Educationdegrees and training on record
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uclahealth.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uclahealth.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uclahealth.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uclahealth.org ↗
- BS
Biological Sciences, University of Southern California
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uclahealth.org ↗ - Board Certified
Hematology, American Board of Internal Medicine
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →onclive.com ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uclahealth.org ↗
Editorial & leadership rolesjournal and society appointments
- Director
Hematological Malignancies Stem Cell Transplant Program, UCLA
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medschool.ucla.edu ↗ - Chair
FEC (Faculty Executive Committee) Governance Sub-Committee, UCLA David Geffen School of Medicine
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medschool.ucla.edu ↗ - Principal Investigator
multiple hematologic malignancy clinical trials (e.g., ZUMA-3, Beat AML Master Trial)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →profiles.ucla.edu ↗
Awards & honorshonors on the public record
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uclahealth.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uclahealth.org ↗
Secondary affiliationsappointments beyond the home institution
- UCLA Health Jonsson Comprehensive Cancer Center
Bowyer Oncology Center
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uclahealth.org ↗ - Ronald Reagan UCLA Medical Center
Hematological Malignancies / Stem Cell Transplantation Unit
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →onclive.com ↗
Media & interviewspress, podcasts and appearances
- Recurring video/written expert contributor
OncLive (author page; topics include AML heterogeneity, JAK inhibitors in myelofibrosis, CAR T-cell therapy, ZUMA-3 trial)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗ - Recurring contributor
Targeted Oncology (author page)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →targetedonc.com ↗ - Video interviews
VJHemOnc (topics include selinexor-based regimens in multiple myeloma, lintuzumab-Ac225 plus venetoclax in R/R AML, MRD conversion in AML)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →vjhemonc.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Online presence
Updated 14 Jul 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accountspublic accounts run by this person
- Doximity
doximity.com/pub/gary-schiller-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - ResearchGate
researchgate.net/profile/Gary-Schiller
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗
Mentions by otherswhere others cite or feature them
- Facebook
facebook.com/OncLive/videos/dr-schiller-and-dr-fazal-on-standard-of-care-treatments-for-bpdcn/308332134209864
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →facebook.com ↗ - Other
onclive.com/authors/gary-j-schiller-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.